Investment Thesis
Annovis Bio is a pre-revenue pharmaceutical company with severe financial distress: zero product revenue, negative free cash flow of -$9M annually, and a current ratio of 0.61x indicating acute liquidity stress. With only ~$14.2M in cash and burning $9M per year, the company faces potential insolvency within 18 months absent significant capital raises or clinical success.
Strengths
- No long-term debt eliminates near-term solvency risk from external creditors
- Maintains positive cash reserves of $14.2M providing limited runway for operations and clinical development
- Biotech/pharma sector expectation of losses during pre-commercial development phase is standard
Risks
- Zero revenue generation with no evidence of commercially viable products
- Negative operating cash flow of -$9M annually with limited cash runway (~1.5 years at current burn rate)
- Current ratio of 0.61x signals short-term liquidity crisis and potential inability to meet obligations
- Massive operating losses of -$18M indicate unsustainable business model without product approval
- Severely negative returns (ROE -563%, ROA -108%) demonstrate substantial shareholder value destruction
Key Metrics to Watch
- Quarterly cash burn rate and months of cash remaining
- Clinical trial progression milestones and FDA regulatory updates
- Capital raise announcements and dilutive financing events
- Licensing or partnership agreements that could generate revenue
Financial Metrics
Revenue
0.0
Net Income
-17.6M
EPS (Diluted)
$-0.63
Free Cash Flow
-9.0M
Total Assets
16.2M
Cash
14.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-563.2%
ROA
-108.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.61x
Quick Ratio
0.61x
Debt/Equity
0.00x
Debt/Assets
80.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T07:39:15.753147 |
Data as of: 2026-03-31 |
Powered by Claude AI